Get the app
USHealthcare

Trulieve Cannabis Corp. (TRLV)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$11.65+0.87%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$271.0M
Revenue YoY
-10.3%
Net profit
$-406.1M
EPS
$0.11
EPS estimate
$0.03
Net margin
-149.9%

EPS came in at 0.11 against a street estimate of 0.03 — a beat of 266.7%.

Key statistics

Market cap
$2.23B
Forward P/E
22.8
P/B
2.92
Book value
$6.07
EPS (TTM)
$-2.44
52-week high
$13.28
52-week low
$7.17
50-day MA
$9.77
200-day MA
$8.25
Beta
1.76

Analyst view

with an average price target of $18.18.

Shareholding

Insiders
1.34%
Institutions
21.40%

Largest institutional holders

FundStake
AdvisorShares Investments, LLC5.53%
Oakmont Corp0.78%
NANO CAP NEW MILLENNIUM GROWTH FUND L P0.08%
Bluechip Wealth Advisors LLC0.06%
JW Asset Management, LLC0.04%
Harbor Advisors LLC0.02%
Albert D Mason Inc0.02%
Zurcher Kantonalbank0.02%

Recent filings & reports

DocumentDate
Material agreement · Q3 2026
TRULIEVE CANNABIS CORP. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Trulieve Cannabis Corp., traded as TRLV on NYSE • Headquarters: 3494 Martin H
2026-08-11
Quarterly report · Q2 2026
TRULIEVE CANNABIS CORP. — Q2 2026 SUMMARY HEADLINE NUMBERS • Revenue Q2 2026: $270.952 million (down from $302.086 million Q2 2025) • Revenue H1 202
2026-08-07
Acquisition completed · Q3 2026
TRULIEVE CANNABIS CORP. - FORM 8-K SUMMARY HEADLINE NUMBERS • Filing Date: August 7, 2026 • Reporting Period: Three and six months ended June 30, 20
2026-08-07
Shareholder vote results · Q3 2026
TRULIEVE CANNABIS CORP. - FORM 8-K SUMMARY HEADLINE NUMBERS • Special shareholder meeting held August 5, 2026 • Delaware Domestication proposal: 71,
2026-08-05
Board / officer change · Q2 2026
TRULIEVE CANNABIS CORP. - FORM 8-K SUMMARY HEADLINE NUMBERS • Report Date: June 30, 2026 • Company: Trulieve Cannabis Corp. (Ticker: TRLV, NYSE) • H
2026-07-02
Proxy statement · Q2 2026
TRULIEVE CANNABIS CORP. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Delaware Domestication — Special resolution to appro
2026-06-25
Quarterly report · Q1 2026
TRULIEVE CANNABIS CORP. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $286.8 million (down 3.7% from $297.8 million in Q1 2025) • Gross
2026-05-07
Proxy statement · Q4 2025
TRULIEVE CANNABIS CORP. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Set the number of directors at 7 (requires
2026-04-29

Readable in the app.

Deals & corporate news

AnnouncementDate
Board authorizes $50M share repurchase program over 12 months
Trulieve Cannabis Corp. announced a share repurchase program on June 9, 2026, authorizing the company to buy back up to $50 million worth of its own stock, or a maximum of 8,495,038 shares (
2026-06-09
$100M Senior Secured Notes issued for capital expenditures and corporate purposes
Trulieve Cannabis Corp. announced on December 8, 2025, that it secured $100 million in commitments for senior secured notes due in 2030. Key terms: The notes carry a 10.5% annual interest ra
2025-12-09

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Trulieve Cannabis Corp. — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.